Consensus recommendations for the use of FEIBA® in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery
Consensus recommendations for the use of FEIBA® in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery
Summary: A growing number of publications have described the efficacy and safety of FEIBA as a first-line haemostatic agent for surgical procedures in haemophilia A patients with high-responding FVIII inhibitors. The aim of this study was to provide practical guidance on patient management and selection and also to communicate a standardized approach to the dosing and monitoring of FEIBA during and after surgery. A consensus group was convened with the aims of (i) providing an overview of the efficacy and safety of FEIBA in surgery; (ii) sharing best practice; (iii) developing recommendations based on the outcome of (i) and (ii). To date there have been 17 publications reporting on the use of FEIBA in over 210 major and minor orthopaedic and non-orthopaedic surgical procedures. Haemostatic outcome was rated as 'excellent' or 'good' in 78-100% of major cases. The reporting of thromboembolic complications or anamnestic response to FEIBA was very rare. Key to the success of FEIBA as haemostatic cover in surgery is to utilize the preplanning phase to prepare the patient both for surgery and also for rehabilitation. Haemostatic control with FEIBA should be continued for an adequate period postoperatively to support wound healing and to cover what can in some patients be an extended period of physiotherapy. Published data have demonstrated that FEIBA can provide adequate, well tolerated, peri and postoperative haemostatic cover for a variety of major and minor surgical procedures in patients with haemophilia A. The consensus recommendations provide a standardized approach to the dosing and monitoring of FEIBA.
Activated prothrombin complex concentrates, Bypassing agents, FEIBA, Haemophilia, Inhibitors, Surgery
294-303
Rangarajan, S.
9a5e4c7e-55ba-4a3a-b5f6-f1e269d927c3
Austin, S.
a4948d0e-c6fb-43e8-b3d2-7a46b93433bf
Goddard, N. J.
dc544c8b-8bca-45fe-b1df-4e9ec09e2b64
Négrier, C.
d1f0a2d3-4055-4a6c-b895-533894070c5c
Rodriguez-Merchan, E. C.
57c9940e-83a8-4da4-aba6-aabcfa699e28
Stephensen, D.
1b335208-1ab1-4fd7-811f-923c7297eeff
Yee, T. T.
b268a19d-ef5f-47f2-af65-505bc03ed98d
1 March 2013
Rangarajan, S.
9a5e4c7e-55ba-4a3a-b5f6-f1e269d927c3
Austin, S.
a4948d0e-c6fb-43e8-b3d2-7a46b93433bf
Goddard, N. J.
dc544c8b-8bca-45fe-b1df-4e9ec09e2b64
Négrier, C.
d1f0a2d3-4055-4a6c-b895-533894070c5c
Rodriguez-Merchan, E. C.
57c9940e-83a8-4da4-aba6-aabcfa699e28
Stephensen, D.
1b335208-1ab1-4fd7-811f-923c7297eeff
Yee, T. T.
b268a19d-ef5f-47f2-af65-505bc03ed98d
Rangarajan, S., Austin, S., Goddard, N. J., Négrier, C., Rodriguez-Merchan, E. C., Stephensen, D. and Yee, T. T.
(2013)
Consensus recommendations for the use of FEIBA® in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery.
Haemophilia, 19 (2), .
(doi:10.1111/hae.12028).
Abstract
Summary: A growing number of publications have described the efficacy and safety of FEIBA as a first-line haemostatic agent for surgical procedures in haemophilia A patients with high-responding FVIII inhibitors. The aim of this study was to provide practical guidance on patient management and selection and also to communicate a standardized approach to the dosing and monitoring of FEIBA during and after surgery. A consensus group was convened with the aims of (i) providing an overview of the efficacy and safety of FEIBA in surgery; (ii) sharing best practice; (iii) developing recommendations based on the outcome of (i) and (ii). To date there have been 17 publications reporting on the use of FEIBA in over 210 major and minor orthopaedic and non-orthopaedic surgical procedures. Haemostatic outcome was rated as 'excellent' or 'good' in 78-100% of major cases. The reporting of thromboembolic complications or anamnestic response to FEIBA was very rare. Key to the success of FEIBA as haemostatic cover in surgery is to utilize the preplanning phase to prepare the patient both for surgery and also for rehabilitation. Haemostatic control with FEIBA should be continued for an adequate period postoperatively to support wound healing and to cover what can in some patients be an extended period of physiotherapy. Published data have demonstrated that FEIBA can provide adequate, well tolerated, peri and postoperative haemostatic cover for a variety of major and minor surgical procedures in patients with haemophilia A. The consensus recommendations provide a standardized approach to the dosing and monitoring of FEIBA.
This record has no associated files available for download.
More information
Accepted/In Press date: 20 August 2012
e-pub ahead of print date: 19 September 2012
Published date: 1 March 2013
Keywords:
Activated prothrombin complex concentrates, Bypassing agents, FEIBA, Haemophilia, Inhibitors, Surgery
Identifiers
Local EPrints ID: 442897
URI: http://eprints.soton.ac.uk/id/eprint/442897
ISSN: 1351-8216
PURE UUID: a3b0c0ed-8200-47e8-aad6-1b1e673b93cc
Catalogue record
Date deposited: 30 Jul 2020 16:34
Last modified: 17 Mar 2024 04:02
Export record
Altmetrics
Contributors
Author:
S. Austin
Author:
N. J. Goddard
Author:
C. Négrier
Author:
E. C. Rodriguez-Merchan
Author:
D. Stephensen
Author:
T. T. Yee
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics